Combat minimal residual disease (MRD) to revolutionize leukemia treatmentMIRACLE is a Marie Skłodowska-Curie doctoral network aiming to educate a new generation of researchers optimally equipped to advance and accelerate development of novel therapeutics directed to leukemia MRD, and to progress effective treatments to the clinic.
Reprogramming Immunity: A Cheaper, Faster Future for CAR-T Therapy?A groundbreaking shift in cancer immunotherapy may be on the horizon. While CAR-T cell therapy has proven remarkably effective in treating certain blood cancers, its complex and costly manufacturing process has limited widespread use. Now, a new approach developed by researchers at the University of Pennsylvania and Capstan Therapeutics could simplify treatment, by training the immune system inside the body. Dutch hematologist Prof. Marie José Kersten weighs in on the promise, challenges, and potential impact of this living therapy’s next evolution.
